Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152).Flygare, J.A., Beresini, M., Budha, N., Chan, H., Chan, I.T., Cheeti, S., Cohen, F., Deshayes, K., Doerner, K., Eckhardt, S.G., Elliott, L.O., Feng, B., Franklin, M.C., Reisner, S.F., Gazzard, L., Halladay, J., Hymowitz, S.G., La, H., Lorusso, P., Maurer, B., Murray, L., Plise, E., Quan, C., Stephan, J.P., Young, S.G., Tom, J., Tsui, V., Um, J., Varfolomeev, E., Vucic, D., Wagner, A.J., Wallweber, H.J., Wang, L., Ware, J., Wen, Z., Wong, H., Wong, J.M., Wong, M., Wong, S., Yu, R., Zobel, K., Fairbrother, W.J.
(2012) J Med Chem 55: 4101-4113
- PubMed: 22413863
- DOI: https://doi.org/10.1021/jm300060k
- Primary Citation of Related Structures:
- PubMed Abstract:
A series of compounds were designed and synthesized as antagonists of cIAP1/2, ML-IAP, and XIAP based on the N-terminus, AVPI, of mature Smac. Compound 1 (GDC-0152) has the best profile of these compounds; it binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with K(i) values of 28, 14, 17, and 43 nM, respectively. These compounds promote degradation of cIAP1, induce activation of caspase-3/7, and lead to decreased viability of breast cancer cells without affecting normal mammary epithelial cells. Compound 1 inhibits tumor growth when dosed orally in the MDA-MB-231 breast cancer xenograft model. Compound 1 was advanced to human clinical trials, and it exhibited linear pharmacokinetics over the dose range (0.049 to 1.48 mg/kg) tested. Mean plasma clearance in humans was 9 ± 3 mL/min/kg, and the volume of distribution was 0.6 ± 0.2 L/kg.
Department of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA. email@example.com